about
Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptidesIdentification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3Estimating point and interval frequency of antigen-specific CD4+ T cells based on short in vitro expansion and improved poisson distribution analysisNon-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patientsCancer immunotherapy: synthetic and natural peptides in the balance.Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.Immune infiltrates as predictive markers of survival in pancreatic cancer patients.Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies.Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival.The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.Serological immunoreactivity against colon cancer proteome varies upon disease progression.Tumor-derived factors affecting immune cells.Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates.T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients.Acetylcholine receptor-specific CD4+ T cells in myasthenia gravis patients have individual, but restricted TCR V beta usage.TCR V beta usage by acetylcholine receptor-specific CD4+ T cells in myasthenia gravis.Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer.Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells.Quantitative and Qualitative Analysis of Tumor-Associated CD4⁺ T Cells.T-cell receptor-mediated cross-allergenicity.Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matricesImmunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motifMAGE-A3161–175 contains an HLA-DRβ4 restricted natural epitope poorly formed through indirect presentation by dendritic cellsCD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopesDendritic cell-derived IL-2 production is regulated by IL-15 in humans and in miceConstitutive expression of the heat shock protein 72 kDa in human melanoma cellsMolecular mimicry among human autoantigens
P50
Q25257170-F6D36DD3-31FD-439E-9F9D-C6738FB6655BQ28209661-E03EDE05-3E26-4335-A3D6-288E929C6911Q31082473-49946720-E6F9-4D51-BBCC-1A5CAE90E6B2Q33508227-A82B1ACC-E759-4CA7-83D4-89883F4BAD14Q33740203-F04A9146-3324-4D53-AAF9-2F509CD716ABQ34681333-87DDB4C0-E194-4B6E-A3F7-C1C5E580CAFBQ38129379-96B66FEA-3FC4-46D5-89C9-F97DC7ED063EQ38196935-DBC5CA90-BA71-466E-B6B6-01BC2B0CD222Q38855371-CA068E5D-F31A-4415-AD50-198882CF281EQ39725034-44C7BA8B-9F5E-4777-BBF1-790AD7449D1EQ40027849-4191B015-DD6E-4611-8CFF-FC658CD6FFDEQ40175378-DC7BC1B2-11F7-41F3-90F2-61D68607697FQ40436128-16DD45E0-6B3F-47AF-A541-2F98163798CCQ40441654-20CFA2C3-0E31-4BC5-BE1E-DD7D537987A9Q40448718-1F716E1A-5C29-4140-BFBB-8ACD20E78A33Q40792814-C76025EC-A678-4B6B-B7B5-6430DFFE26ABQ41024195-972D03E3-D953-4428-B916-70E6AC1B20E1Q41117699-A20ECDE3-AF61-42B7-AAD6-1510FA8782B2Q42204278-5DFA52CA-F8E1-4CD0-A129-5416C99456C7Q42595560-DB4CAA63-9C25-4D35-956E-503C30273F92Q45375334-88DB1367-2BC2-400D-8006-BAD09C2D9050Q46575651-8FF1BD7D-6483-4045-B518-C1C49A9214B4Q46721086-1666032A-41C4-427C-BED8-323D38039730Q54518729-989656CE-683F-43EF-871B-76FFDDB45D10Q54690464-F4D8518F-906C-4180-8A42-ED2E3159E6F5Q57221639-A73A1F7A-BE73-4FD2-ACA3-C9DD6A1E4877Q57795071-8D7BE532-DDD0-4E54-901F-7C3327971DB0Q58880793-7D0F3878-4914-4AE7-91CC-669981D1E1E3Q58880796-7958DDC1-F55E-4D1B-B301-07B9856B1B5FQ58880798-D53766DA-5CE3-4D2C-A185-5F49226780E7Q58880799-44305357-FEFE-449F-84ED-F3CE597F08BCQ58880800-BEEA6B8B-25B7-469B-99CE-EB2F0B30FA01
P50
description
researcher ORCID ID = 0000-0001-9079-2336
@en
wetenschapper
@nl
name
Maria Pia Protti
@ast
Maria Pia Protti
@en
Maria Pia Protti
@es
Maria Pia Protti
@nl
type
label
Maria Pia Protti
@ast
Maria Pia Protti
@en
Maria Pia Protti
@es
Maria Pia Protti
@nl
prefLabel
Maria Pia Protti
@ast
Maria Pia Protti
@en
Maria Pia Protti
@es
Maria Pia Protti
@nl
P1053
J-7899-2016
P106
P1153
7006160984
P21
P2798
P31
P3829
P496
0000-0001-9079-2336